Pasithea Therapeutics Corp (KTTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $17.44M
Last updated: Nov 17, 2026 at 4:10 PM ET
Pasithea Therapeutics Corp (KTTA) Statistics
Pasithea Therapeutics (KTTA) has a market cap of $17.44M. Its share count is up 348.90% from a year earlier. It holds $41.22M more cash than debt, 236.31% of its market cap.
Total Valuation
| Market Cap | $17.44M |
|---|---|
| Latest price (Nov 17, 2026) | $0.43 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/B Ratio | 0.3x |
|---|---|
| P/TBV Ratio | 0.4x |
Price Statistics
The stock is down 39.50% over 52 weeks and trades 10.42% below its 50-day average.
| Beta (1Y) | 1.15 |
|---|---|
| 52-Week Change | -39.50% |
| 1-Month Change | +5.34% |
| 3-Month Change | -11.37% |
| 6-Month Change | -38.19% |
| 5-Year Change | -99.35% |
| Total Return (1Y) | -39.50% |
| Total Return (3Y CAGR) | -58.77% |
| Total Return (5Y CAGR) | -61.00% |
| Max Drawdown (1Y) | -74.97% |
| Max Drawdown (3Y) | -96.80% |
| Sharpe Ratio (1Y) | -0.32 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $0.48 |
| 200-Day Average | $0.61 |
| 52-Week Range | $0.28 to $2.06 |
| RSI (14 Days) | 43.5 |
| Average Volume (20 Days) | 1.85M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 15.67x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 15.67x |
|---|---|
| Quick Ratio | 15.67x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -56.78% over the last 12 months, against a 5-year average of -47.26%.
| Return on Equity (ROE) | -56.78% |
|---|---|
| Return on Assets (ROA) | -53.42% |
| ROE (5Y Average) | -47.26% |
| ROA (5Y Average) | -43.30% |
| ROIC (5Y Average) | -36.71% |
Scores
KTTA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$157.96K |
| Operating Income | -$27.82M |
| Pretax Income | -$24.83M |
| Net Income | -$24.83M |
| Reported EPS (TTM) | -$1.37 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.06% of the $46.49M in total assets.
| Cash and Equivalents | $41.22M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.22M |
| Net Cash Per Share | $1.23 |
| Working Capital | $40.43M |
| Shareholder Equity | $43.73M |
| Book Value Per Share | $1.31 |
| Tangible Book Value | $40.43M |
| Tangible Book Per Share | $1.21 |
| Total Assets | $46.49M |
| Total Liabilities | $2.76M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$19.38M |
|---|---|
| FCF Per Share | -$0.58 |
| Depreciation and Amortization | $630.16K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -40.87% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -26.73% |
Dividends and Yields
KTTA does not pay a dividend.
| Buyback Yield | -382.45% |
|---|---|
| Shareholder Yield | -382.45% |
Stock Splits
The last split was a 1-for-20 reverse split on Jan 2, 2024.
| Last Split Date | Jan 2, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KTTA
What is KTTA's market cap?
Pasithea Therapeutics has a market cap of $17.44M.
How many shares of KTTA are outstanding?
Pasithea Therapeutics has 33.41M shares outstanding. The count is up 348.90% from a year earlier.
Does KTTA pay a dividend?
No. Pasithea Therapeutics does not pay a dividend.
How much debt does KTTA have?
Pasithea Therapeutics has $0 of total debt and $41.22M of cash and equivalents, a net cash position of $41.22M.
KTTA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors